The University of Texas System

Ut Southwestern Medical Center

Lin Li

Hidetaka Suzuki

Xiaodong Wang

Jef K. De Brabander

Patrick G. Harran

Ranny Mathew Thomas

Jef K De Brabander

Steven L McKnight

Joseph Ready

Andrew A Pieper

Yusheng Wu

Jeffrey M Zigman

Xin Jiang

Patrick G Harran

Andew A Pieper

Jerry W Shay

Wentian Wang

Bo Liu

Pano Theodoropoulos

Deepak Nijhawan

Joseph M Ready

Steven L Mcknight

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

Anti-depression compounds

This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protecting from neuron cell death.

Pro-neurogenic compounds

The described invention provides methods for targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis.

Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis

The described invention provides small molecule anti-cancer compounds that selectively target and inhibit measurable biological activity of truncated APC proteins, an immortalized Human Colonic Epithelial Cell (HCEC) model, and pharmaceutical compositions comprising at least one of the small molecule anti-cancer compounds and a pharmaceutically acceptable carrier.

Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins

This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protection from neuron cell death.

Methods for treating Parkinson's disease using pro-neurogenic compounds

Growing community of inventors

Flower Mound, TX, United States of America

Jef K De Brabander